Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Licenses Nutrition 21’s Chromax In Patent Claim Settlement

This article was originally published in The Tan Sheet

Executive Summary

The settlement terms are confidential, but Pfizer “acknowledged the validity of Nutrition 21’s asserted patents” and the Centrum line “may continue to use chromium picolinate,” Nutrition 21 says. The firms agreed as attorneys prepared to begin questioning a pool of potential jurors for the trial.

You may also be interested in...



Industry Roundup: Nature’s Way Licenses Chromax, Tauriga moves to supplements

Nutrition 21, Nature’s Way settle patent case; Tauriga moves from food to supplements; Miami firm banned from weight loss market; national sales for Mary’s Nutritionals; and more news in brief.

Industry Roundup: Nature’s Way Licenses Chromax, Tauriga moves to supplements

Nutrition 21, Nature’s Way settle patent case; Tauriga moves from food to supplements; Miami firm banned from weight loss market; national sales for Mary’s Nutritionals; and more news in brief.

In Brief: Endo Buys Somar; Neptune, Enzymotec Settle Dispute; FDA Prohibits Omega-3 Nutrient Claims

Endo buys Somar; Neptune, Enzymotec settle patent infringement; FDA prohibits omega-3 nutrient claims; “Sell through” for herbals ends in U.K.; C&D licenses Nutrition 21’s chromium picolinate; Arizona DXM bill and Iowa Select Herbs drug claims.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS106792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel